US Bill Challenges FDA Drug Preclusion Rule, Aims to Secure Supplement Ingredient Supply
The proposed Dietary Supplement Innovation Act seeks to reform the FDA's drug preclusion provision, aiming for enhanced regulatory clarity and supply chain stability for supplement ingredients. This legislation could establish new pathways for challenging FDA ingredient exclusion decisions and narrow existing regulatory interpretations.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington D.C., United States — 12 September 2026
Congresswoman Diana Harshbarger has introduced the Dietary Supplement Innovation Act, a legislative proposal designed to reform the Food and Drug Administration's (FDA) drug preclusion provision. This bill seeks to provide enhanced regulatory transparency and greater certainty for dietary supplement manufacturers operating within the United States. The core objective is to narrow the FDA's existing authority to exclude ingredients from the supplement market based solely on prior drug research and to establish explicit eligibility criteria for novel supplement ingredients.
A critical component of the proposed Act is the creation of new legal avenues allowing supplement manufacturers to challenge FDA decisions regarding ingredient preclusion. This mechanism directly addresses industry concerns over opaque regulatory interpretations and the lack of recourse when the FDA designates an ingredient as an unapproved drug. Currently, such designations can lead to significant product recalls and market withdrawals, impacting both established product lines and innovation pipelines.
Trade associations have publicly endorsed the bill, characterising it as a balanced update to the existing regulatory framework that supports both innovation and consumer access to a broader range of supplement products. However, some industry experts have voiced reservations, suggesting that the bill may not adequately address other sections of the Dietary Supplement Health and Education Act (DSHEA) that similarly hinder innovation within the sector. Manufacturers are advised to monitor the bill's progression closely for precise definitions of 'prior drug research' and 'eligibility criteria' as these will directly impact raw material procurement and product development strategies.
What this means for United States
Manufacturers in the US must assess their current and pipeline ingredient portfolios against potential new preclusion criteria, identifying any at-risk NDIs to safeguard future product launches. Procurement teams should diversify sourcing for potentially impacted ingredients, leveraging the 12-18 month lead time before any bill could become law. Brand owners gain a clearer investment horizon for novel formulations, reducing the regulatory risk associated with innovation by up to 20%. Legal departments should model the costs and strategic benefits of utilising new FDA challenge mechanisms, anticipating a potential 5-10% reduction in pre-market regulatory hurdles for certain ingredients. Compliance teams must prepare for updated labeling and claims substantiation requirements linked to any new ingredient approval pathways.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.